Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology
Main Authors: Arra, Aditya, Pech, Maximilian, Fu, Hang, Lingel, Holger, Braun, Franziska, Beyer, Christian, Spiliopoulou, Myra, Bröker, Barbara M., Lampe, Karen, Arens, Christoph, Vogel, Katrin, Pierau, Mandy, Brunner-Weinzierl, Monika C.
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2021
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8204976/
https://ncbi.nlm.nih.gov/pubmed/34178430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1938475
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items